SCHEMBL3358546

SCHEMBL3358546

CCC1CC(=O)C=C2CC[C@@H]3[C@H](CC[C@]4(CC)CCC[C@@H]34)[C@H]21

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 9/20 0.40
▸ AR P10275 8/20 0.38
▸ CYP19A1 P11511 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ SLC6A4 P31645 2/20 0.38
▸ SHBG P04278 2/20 0.38
▸ NR3C1 P04150 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ ABCB11 O95342 1/20 0.38
▸ ESR1 P03372 1/20 0.38
▸ NR3C2 P08235 3/20 0.37
▸ SERPINA6 P08185 2/20 0.36
▸ SLC22A1 O15245 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10705595 0.87 SHBG (0.41) PGRARCYP19A1MEN1CYP3A4
SCHEMBL3354407 0.86 PGR (0.38) PGRARCYP19A1MEN1CYP3A4
SCHEMBL9947825 0.85 CYP19A1 (0.42) PGRARCYP19A1SHBGNR3C2
SCHEMBL9116613 0.80 CYP19A1 (0.60) PGRARCYP19A1MEN1CYP3A4
SCHEMBL8209833 0.79 CYP19A1 (0.59) CYP19A1LMNASHBGSERPINA6ALDH1A1
SCHEMBL3359911 0.79 PGR (0.38) PGRARCYP19A1MEN1CYP3A4
SCHEMBL3645097 0.78 CYP19A1 (0.41) PGRARCYP19A1MEN1CYP3A4
SCHEMBL7705294 0.76 SHBG (0.61) PGRARCYP19A1CYP3A4LMNA
SCHEMBL5552057 0.76 SHBG (0.61) PGRARCYP19A1CYP3A4LMNA
SCHEMBL29496903 0.76 SHBG (0.61) PGRARCYP19A1CYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010066354-A1 USE OF 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR MANUFACTURING A MEDICAMENT IN A SUSTAINED-RELEASE FORM FOR PARENTERAL USE, AND SUSTAINED-RELEASE MEDICAMENT CONTAINING 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR PARENTERAL USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-17 — — WO disclosed
EP-2178899-A1 17BETA-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE Bayer Schering Pharma Aktiengesellschaft (DE) 2010-04-28 — — EP disclosed
WO-2008151745-A1 17BETA-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 — — WO disclosed
Send feedback